Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...

ACTOFIT uses a continuous glucose monitor (Freestyle Libre CGM) to provide intelligent nudges based on glucose biomarkers. The FreeStyle Libre CGM sensor can be easily applied and stays on the back of ...

Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

DexCom ( DXCM -2.62%) is not a stock that investors should be rushing to sell. It has a few different opportunities to ...

Given every human being is totally unique, it’s no surprise our bodies often behave in different ways. So, while you should ...

Abbott is working to integrate its newest continuous glucose monitor (CGM) with Beta Bionics’ automated insulin delivery (AID) system. The companies plan to connect Beta Bionics’ iLet Bionic Pancreas ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...